FOLLOW US

In a seismic shift for AI-powered healthcare, Navina has clinched a staggering $55 million Series C funding round, supercharging its quest to redefine clinical intelligence. This latest infusion rockets the company’s total funding to a formidable $100 million, cementing its position as a vanguard in the field.

Fueling the Future of AI-Driven Healthcare

Navina, a New York-based artificial intelligence company specializing in clinical intelligence, announced on Tuesday that the funds will be channeled into advancing its proprietary AI technology. The goal? To become the gold standard in unified patient data, seamlessly enhancing both efficiency and care quality for healthcare providers and payers.

The company’s cutting-edge platform serves as a real-time co-pilot for clinicians, delivering precision-driven insights that elevate both patient outcomes and financial efficiency. Already entrenched in 1,300 clinics and trusted by over 10,000 healthcare professionals, Navina is rapidly reshaping the healthcare landscape.

Goldman Sachs Leads the Charge

The Series C round was spearheaded by Growth Equity at Goldman Sachs Alternatives, with robust backing from returning investors such as Vertex Ventures Israel, Grove Ventures, and Alive. This investment underscores a resounding vote of confidence in Navina’s vision of harnessing AI to dismantle data silos and revolutionize patient care.

"This investment is a powerful validation of Navina's vision to improve patient outcomes and healthcare economics by breaking down data barriers with AI," said Ronen Lavi, Navina’s co-founder and CEO. "Goldman Sachs' market leadership will be instrumental as we enter this pivotal growth phase. With this capital, we will accelerate AI innovation and make every patient interaction more empathetic, personalized, and proactive."

Expanding Across the U.S. Healthcare Market

The fresh capital injection will also turbocharge Navina’s expansion across the U.S., allowing it to integrate AI-driven intelligence into every outpatient interaction. With artificial intelligence rapidly redefining healthcare, Navina is poised to lead the charge.

"Navina stands at the forefront of AI-driven transformation in healthcare," said Irit Kahan, managing director in Growth Equity at Goldman Sachs Alternatives. "Their deep integration into clinical workflows and unmatched provider trust position them to drive meaningful impact across the healthcare ecosystem. We believe their AI-powered platform is a game-changer."

A Game-Changer in Clinical Intelligence

As AI takes center stage in modern medicine, Navina’s trajectory signals a paradigm shift in how clinicians access and utilize patient data. The investment, guided by Meitar’s Raanan Lerner, is set to propel the company into new frontiers, ensuring that AI isn’t just an accessory in healthcare—but the foundation of its future.